Mouse lymphosarcomas sensitive and resistant to cyclophosphamide therapy: activity of cathepsins B, L, and D during various schemes of treatment with cyclophosphamide and SE-glycan.
D000276:Adjuvants, Immunologic / Q000494:pharmacology; D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000494:pharmacology*; D002401:Cathepsin B / Q000378:metabolism; D002402:Cathepsin D / Q000378:metabolism; D056668:Cathepsin L; D002403:Cathepsins / Q000378:metabolism*; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000494:pharmacology*; D003546:Cysteine Endopeptidases; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D004357:Drug Synergism; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D008297:Male; D051379:Mice; D008808:Mice, Inbred CBA; D009368:Neoplasm Transplantation; D011134:Polysaccharides / Q000008:administration & dosage / Q000737:chemistry / Q000494:pharmacology*
D000276:Adjuvants, Immunologic; D018906:Antineoplastic Agents, Alkylating; D011134:Polysaccharides; D003520:Cyclophosphamide; D002403:Cathepsins; D003546:Cysteine Endopeptidases; D002401:Cathepsin B; D056668:Cathepsin L; C534278:Ctsl protein, mouse; D002402:Cathepsin D